title: Difference in mode of action of cimetidine and gefarnate on endogenous prostacyclin, prostaglandin E2 and thromboxane in rat gastric mucosa.
abstract: The effects of cimetidine and gefarnate on endogenous prostacyclin, prostaglandin E2 and thromboxane were studied in vivo in rat gastric mucosa. The animals received cimetidine (20 mg/kg, i.p.) and/or gefarnate (100 mg/kg, s.c.) twice a day for 7 days. Gastric mucosal 6-keto-prostaglandin F1 alpha (as prostacyclin), prostaglandin E2 and thromboxane B2 (as thromboxane A2) were determined by radioimmunoassay. Cimetidine reduced prostacyclin, prostaglandin E2, but not thromboxane A2. Gefarnate inhibited the cimetidine-induced reduction of prostacyclin and prostaglandin E2; in cimetidine-untreated controls, it did not produce an increase in those prostaglandins and thromboxane A2 above the normal levels.
mesh_terms: D000818:Animals; D002927:Cimetidine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003864:Depression, Chemical; D015232:Dinoprostone; D011464:Epoprostenol / Q000378:metabolism*; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism*; D005778:Gefarnate / Q000494:pharmacology*; D008297:Male; D011458:Prostaglandins E / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D013729:Terpenes / Q000494:pharmacology*; D013931:Thromboxanes / Q000378:metabolism*
chemical_list: D011458:Prostaglandins E; D013729:Terpenes; D013931:Thromboxanes; D005778:Gefarnate; D002927:Cimetidine; D011464:Epoprostenol; D015232:Dinoprostone